Format
Sort by

Send to

Choose Destination

Links from PubMed

Items: 1 to 20 of 54

1.
2.

Original Antigenic Sin Response to RNA Viruses and Antiviral Immunity.

Park MS, Kim JI, Park S, Lee I, Park MS.

Immune Netw. 2016 Oct;16(5):261-270. Review.

3.

Determination of antigenicity-altering patches on the major surface protein of human influenza A/H3N2 viruses.

Kratsch C, Klingen TR, Mümken L, Steinbrück L, McHardy AC.

Virus Evol. 2016 Feb 14;2(1):vev025.

4.

Complete Protection against Influenza Virus H1N1 Strain A/PR/8/34 Challenge in Mice Immunized with Non-Adjuvanted Novirhabdovirus Vaccines.

Rouxel RN, Mérour E, Biacchesi S, Brémont M.

PLoS One. 2016 Oct 6;11(10):e0164245. doi: 10.1371/journal.pone.0164245.

5.

Positive Selection Drives Rapid Evolution of the meq Oncogene of Marek's Disease Virus.

Padhi A, Parcells MS.

PLoS One. 2016 Sep 23;11(9):e0162180. doi: 10.1371/journal.pone.0162180.

6.

Obesity Outweighs Protection Conferred by Adjuvanted Influenza Vaccination.

Karlsson EA, Hertz T, Johnson C, Mehle A, Krammer F, Schultz-Cherry S.

MBio. 2016 Aug 2;7(4). pii: e01144-16. doi: 10.1128/mBio.01144-16.

7.

Vaccine efficacy and T helper cell differentiation change with aging.

Lefebvre JS, Lorenzo EC, Masters AR, Hopkins JW, Eaton SM, Smiley ST, Haynes L.

Oncotarget. 2016 Jun 7;7(23):33581-94. doi: 10.18632/oncotarget.9254.

8.

Selection of therapeutic H5N1 monoclonal antibodies following IgVH repertoire analysis in mice.

Gray SA, Moore M, VandenEkart EJ, Roque RP, Bowen RA, Van Hoeven N, Wiley SR, Clegg CH.

Antiviral Res. 2016 Jul;131:100-8. doi: 10.1016/j.antiviral.2016.04.001.

9.

Comparative analysis of routes of immunization of a live porcine reproductive and respiratory syndrome virus (PRRSV) vaccine in a heterologous virus challenge study.

Ouyang K, Hiremath J, Binjawadagi B, Shyu DL, Dhakal S, Arcos J, Schleappi R, Holman L, Roof M, Torrelles JB, Renukaradhya GJ.

Vet Res. 2016 Mar 17;47:45. doi: 10.1186/s13567-016-0331-3.

10.

Expression of CD39 on Activated T Cells Impairs their Survival in Older Individuals.

Fang F, Yu M, Cavanagh MM, Hutter Saunders J, Qi Q, Ye Z, Le Saux S, Sultan W, Turgano E, Dekker CL, Tian L, Weyand CM, Goronzy JJ.

Cell Rep. 2016 Feb 9;14(5):1218-31. doi: 10.1016/j.celrep.2016.01.002.

11.

Immunogenicity and Efficacy of A/H1N1pdm Vaccine Among Subjects With Severe Motor and Intellectual Disability in the 2010/11 Influenza Season.

Hara M, Hanaoka T, Maeda K, Kase T, Ohfuji S, Fukushima W, Hirota Y.

J Epidemiol. 2016 Jun 5;26(6):300-6. doi: 10.2188/jea.JE20150036.

12.

Longitudinal analysis of the peripheral B cell repertoire reveals unique effects of immunization with a new influenza virus strain.

Cortina-Ceballos B, Godoy-Lozano EE, Téllez-Sosa J, Ovilla-Muñoz M, Sámano-Sánchez H, Aguilar-Salgado A, Gómez-Barreto RE, Valdovinos-Torres H, López-Martínez I, Aparicio-Antonio R, Rodríguez MH, Martínez-Barnetche J.

Genome Med. 2015 Nov 25;7:124. doi: 10.1186/s13073-015-0239-y.

13.

H3N2 Mismatch of 2014-15 Northern Hemisphere Influenza Vaccines and Head-to-head Comparison between Human and Ferret Antisera derived Antigenic Maps.

Xie H, Wan XF, Ye Z, Plant EP, Zhao Y, Xu Y, Li X, Finch C, Zhao N, Kawano T, Zoueva O, Chiang MJ, Jing X, Lin Z, Zhang A, Zhu Y.

Sci Rep. 2015 Oct 16;5:15279. doi: 10.1038/srep15279.

14.

Induction of Broad-Based Immunity and Protective Efficacy by Self-amplifying mRNA Vaccines Encoding Influenza Virus Hemagglutinin.

Brazzoli M, Magini D, Bonci A, Buccato S, Giovani C, Kratzer R, Zurli V, Mangiavacchi S, Casini D, Brito LM, De Gregorio E, Mason PW, Ulmer JB, Geall AJ, Bertholet S.

J Virol. 2015 Oct 14;90(1):332-44. doi: 10.1128/JVI.01786-15.

15.

Overview of Serological Techniques for Influenza Vaccine Evaluation: Past, Present and Future.

Trombetta CM, Perini D, Mather S, Temperton N, Montomoli E.

Vaccines (Basel). 2014 Oct 13;2(4):707-34. doi: 10.3390/vaccines2040707. Review.

16.

Active Immunization with Extracellular Vesicles Derived from Staphylococcus aureus Effectively Protects against Staphylococcal Lung Infections, Mainly via Th1 Cell-Mediated Immunity.

Choi SJ, Kim MH, Jeon J, Kim OY, Choi Y, Seo J, Hong SW, Lee WH, Jeon SG, Gho YS, Jee YK, Kim YK.

PLoS One. 2015 Sep 2;10(9):e0136021. doi: 10.1371/journal.pone.0136021.

17.

Enhanced Influenza Virus-Like Particle Vaccination with a Structurally Optimized RIG-I Agonist as Adjuvant.

Beljanski V, Chiang C, Kirchenbaum GA, Olagnier D, Bloom CE, Wong T, Haddad EK, Trautmann L, Ross TM, Hiscott J.

J Virol. 2015 Oct;89(20):10612-24. doi: 10.1128/JVI.01526-15.

18.

B Cells and Functional Antibody Responses to Combat Influenza.

Lofano G, Kumar A, Finco O, Del Giudice G, Bertholet S.

Front Immunol. 2015 Jun 30;6:336. doi: 10.3389/fimmu.2015.00336. Review.

19.

Age-Associated Failure To Adjust Type I IFN Receptor Signaling Thresholds after T Cell Activation.

Li G, Ju J, Weyand CM, Goronzy JJ.

J Immunol. 2015 Aug 1;195(3):865-74. doi: 10.4049/jimmunol.1402389.

20.

Single dose vaccination of the ASO3-adjuvanted A(H1N1)pdm09 monovalent vaccine in health care workers elicits homologous and cross-reactive cellular and humoral responses to H1N1 strains.

Lartey S, Pathirana RD, Zhou F, Jul-Larsen Å, Montomoli E, Wood J, Cox RJ.

Hum Vaccin Immunother. 2015;11(7):1654-62. doi: 10.1080/21645515.2015.1048939.

Items per page

Supplemental Content

Support Center